Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Source: View publication →
The POSEIDON trial demonstrated that a limited course of the anti-CTLA-4 antibody tremelimumab added to durvalumab and platinum-based chemotherapy significantly improved overall and progression-free survival compared to chemotherapy alone in first-line metastatic NSCLC.
Key Findings
Study Design
Study Limitations
Clinical Significance
The POSEIDON results establish a limited-duration anti-CTLA-4 plus anti-PD-L1 chemoimmunotherapy regimen as a viable first-line treatment option for metastatic NSCLC, specifically providing a durable benefit that extends to difficult-to-treat patient subgroups and those with low PD-L1 expression.
Historical Context
The POSEIDON trial builds upon the success of the PACIFIC trial (durvalumab in stage III NSCLC) and the CASPIAN trial (durvalumab in extensive-stage SCLC), exploring whether the addition of the CTLA-4 inhibitor tremelimumab could overcome resistance and provide deeper, more durable clinical responses in the first-line metastatic NSCLC setting.
Guided Discussion
High-yield insights from every perspective
Explain the synergistic mechanism behind combining an anti-CTLA-4 agent like tremelimumab with an anti-PD-L1 agent like durvalumab in metastatic NSCLC.
Key Response
CTLA-4 inhibition (tremelimumab) acts primarily during the 'priming' phase of the immune response in the lymph nodes by increasing T-cell diversity and activation. PD-L1 inhibition (durvalumab) acts during the 'effector' phase within the tumor microenvironment to overcome T-cell exhaustion. Combining them targets two distinct phases of the cancer-immunity cycle, theoretically overcoming resistance mechanisms that occur when only one pathway is blocked.
Which specific patient subgroup in the POSEIDON trial appeared to derive a particularly meaningful benefit from the addition of tremelimumab to durvalumab and chemotherapy, especially when compared to historical outcomes?
Key Response
Post-hoc analyses of POSEIDON suggest that patients with STK11, KEAP1, and KRAS mutations—traditionally associated with poor prognosis and 'cold' tumors resistant to PD-(L)1 monotherapy—showed improved outcomes with the triplet (D+T+C) regimen. This makes the POSEIDON regimen a strong clinical consideration for patients with these specific genomic alterations where chemotherapy or PD-L1 inhibitors alone often fail.
Contrast the 'limited course' tremelimumab strategy used in POSEIDON with the dosing schedule of ipilimumab in the CheckMate 9LA trial. How might these differences impact long-term immune-related adverse events (irAEs)?
Key Response
POSEIDON utilized only 5 doses of tremelimumab (a limited course over 16 weeks), whereas CheckMate 9LA utilized ipilimumab every 6 weeks until progression or toxicity. The POSEIDON approach aims to provide the necessary 'priming' stimulus while limiting the cumulative toxicity and late-onset irAEs typically associated with prolonged CTLA-4 blockade, potentially improving the long-term tolerability of the triplet combination.
The POSEIDON trial showed a statistically significant OS benefit for D+T+C over chemotherapy, but the D+C arm did not reach statistical significance for OS. How does this finding influence your decision to use 'dual' vs 'single' checkpoint inhibition in the first-line setting?
Key Response
The failure of the D+C arm to reach OS significance despite a PFS benefit suggests that for many patients, PD-L1 inhibition plus chemotherapy is insufficient to change the natural history of the disease. The OS benefit in the D+T+C arm reinforces the concept that CTLA-4 inhibition provides a survival 'tail' that PD-L1 inhibition alone may not, particularly in PD-L1 low or negative expressors, shifting the practice toward triplets for high-risk clinical phenotypes.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the statistical hierarchy and alpha-spending strategy employed in POSEIDON regarding the dual primary endpoints of PFS and OS. How did the testing sequence affect the interpretability of the D+C arm results?
Key Response
POSEIDON used a complex gatekeeping strategy to control the family-wise error rate across multiple comparisons. Because the alpha was split between PFS and OS and across two experimental arms (D+T+C and D+C), the D+C arm required a very stringent p-value to claim OS significance. Even though D+C showed a numeric improvement, it failed to meet the pre-specified threshold, highlighting the 'statistical penalty' inherent in multi-arm trials with multiple primary endpoints.
Considering the current standard of care established by KEYNOTE-189, how does the control arm of platinum-based chemotherapy in POSEIDON limit the study's internal and external validity for a 2024 editorial perspective?
Key Response
When POSEIDON began, chemotherapy was a standard control. However, by the time of publication, chemo-immunotherapy (e.g., Pembrolizumab/Chemo) became the global standard. A 'tough' reviewer would flag that POSEIDON lacks a direct head-to-head comparison with the current standard of care (PD-1 + Chemo), making it difficult to definitively conclude if D+T+C is superior to the regimens most clinicians are currently using.
Based on the POSEIDON data, should guideline bodies (like NCCN or ESMO) elevate the D+T+C regimen to a 'Preferred' status for all metastatic NSCLC, or should it be restricted to specific PD-L1 strata?
Key Response
Current NCCN guidelines (v2.2024) list D+T+C as a Category 1 recommendation for first-line NSCLC. However, the most robust OS benefit was observed in the PD-L1 <1% and 1-49% groups. Given the toxicity profile of CTLA-4 inhibitors, committees may prioritize it for PD-L1 <1% (similar to CheckMate 9LA) or for patients with STK11/KEAP1 mutations, rather than replacing Pembrolizumab+Chemo for PD-L1 >50% patients where single-agent PD-1 is often sufficient.
Clinical Landscape
Noteworthy Related Trials
KEYNOTE-189 Trial
Tested
Pembrolizumab plus pemetrexed and platinum-based chemotherapy
Population
Patients with previously untreated metastatic non-squamous NSCLC without EGFR or ALK mutations
Comparator
Placebo plus pemetrexed and platinum-based chemotherapy
Endpoint
Overall survival and progression-free survival
MYSTIC Trial
Tested
Durvalumab plus tremelimumab or durvalumab monotherapy
Population
Treatment-naive patients with stage IV NSCLC
Comparator
Platinum-based chemotherapy
Endpoint
Overall survival and progression-free survival in patients with high PD-L1 expression
CheckMate 9LA Trial
Tested
Nivolumab plus ipilimumab combined with limited-duration platinum-doublet chemotherapy
Population
Patients with metastatic NSCLC regardless of PD-L1 expression
Comparator
Platinum-doublet chemotherapy alone
Endpoint
Overall survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis